That question remains unanswered
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight
Products like simethicone or activated charcoal may provide short-term relief, especially during the adjustment phase
Documentation of symptoms, including their timing relative to Ozempic injections and any associated factors, helps guide clinical decision-making
Journal of Child and Adolescent Psychopharmacology, 22(3), 206-214
However, noticeable weight loss typically takes a bit longer, often occurring within 12 to 16 weeks of consistent use